farrukh tauseef awan, md

22
Farrukh Tauseef Awan, MD General information The Ohio State University 320W 10 th Avenue, Columbus, OH – 43210 Tel.: (614) 688-7942 Fax: (614) 366-5970 E-Mail: [email protected] Education August 2006 M. S. (Clinical Research), University of Pittsburgh, Pittsburgh, PA November 2001 M.B.B.S. (M.D.), The Aga Khan University Medical College, Karachi, Pakistan September 1996 Intermediate in Science, Adamjee Science College, Karachi, Pakistan Postdoctoral Training 2008 – 2009 Cell and Molecular Biology Laboratory Training, The Ohio State University, Columbus OH, Mentor: Dr. John C. Byrd 2006 – 2009 Hematology/Oncology Fellowship Training, The Ohio State University, Columbus, OH 2003 – 2006 Internal Medicine Residency Training, The University of Pittsburgh Medical Center, Pittsburgh, PA 2005 – 2006 Cell and Molecular Biology Laboratory Training, University of Pittsburgh Medical Center, Pittsburgh, PA, Mentor: Dr. S. P. S. Monga 2001 – 2003 Research Medical Officer, The Aga Khan University Hospital, Karachi, Pakistan Certification and Licensure Medical license, Ohio, 2013 - Medical license (inactive), Georgia 2009 - 2015 Current Position 2013 – Associate Professor, Division of Hematology, The Ohio State University, Columbus, Ohio Professional Experience and Academic Appointments 2009 – 2013 Assistant Professor, Division of Hematology/Oncology, Georgia Regents University, Augusta, Georgia

Upload: hahuong

Post on 18-Jan-2017

275 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD General information The Ohio State University 320W 10th Avenue, Columbus, OH – 43210 Tel.: (614) 688-7942 Fax: (614) 366-5970 E-Mail: [email protected] Education

August 2006 M. S. (Clinical Research), University of Pittsburgh, Pittsburgh, PA November 2001 M.B.B.S. (M.D.), The Aga Khan University Medical College, Karachi,

Pakistan September 1996 Intermediate in Science, Adamjee Science College, Karachi, Pakistan Postdoctoral Training

2008 – 2009 Cell and Molecular Biology Laboratory Training, The Ohio State University,

Columbus OH, Mentor: Dr. John C. Byrd 2006 – 2009 Hematology/Oncology Fellowship Training, The Ohio State University,

Columbus, OH 2003 – 2006 Internal Medicine Residency Training, The University of Pittsburgh Medical

Center, Pittsburgh, PA 2005 – 2006 Cell and Molecular Biology Laboratory Training, University of Pittsburgh Medical

Center, Pittsburgh, PA, Mentor: Dr. S. P. S. Monga 2001 – 2003 Research Medical Officer, The Aga Khan University Hospital, Karachi, Pakistan Certification and Licensure

Medical license, Ohio, 2013 - Medical license (inactive), Georgia 2009 - 2015

Current Position 2013 – Associate Professor, Division of Hematology, The Ohio State University,

Columbus, Ohio Professional Experience and Academic Appointments

2009 – 2013 Assistant Professor, Division of Hematology/Oncology, Georgia Regents

University, Augusta, Georgia

Page 2: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

2

2012 – 2013 Director of Marketing and Outreach, Georgia Regents University Cancer Center 2012 – 2013 Member – Georgia Regents University Cancer Center Protocol Review and

Management Committee 2010 – 2013 Member – Immunotherapy Discovery Institute, Georgia Regents University

Cancer Research Center Honors and Awards 2015 Best didactic lecture award for Hematology Oncology fellowship lecture series on

Chronic Lymphocytic Leukemia, at The Ohio State University, September 2015 2013 Georgia Regents University Faculty Senate “Outstanding Young Clinical

Science Faculty Award” 2013 Lymphoma Research Foundation “Clinical Career Development Award”

2010 Selected participant of the American Society of Hematology “Clinical Research

Training Institute” at La Jolla, CA

2008 American Society of Clinical Oncology (ASCO) “Young Investigator Award” 2007 Selected participant of the ASCO/AACR “Methods in Clinical Cancer Research

Workshop” at Vail, CO

2007 Selected participant of the “Molecular and Translational Oncology Workshop” of the Cancer Education Consortium, Amelia Island, FL.

1996 Awarded scholarship and Governor’s Silver Medal by the Board of Intermediate

Education, Karachi, Pakistan for securing second position among 20,000 candidates

Professional Memberships and Activities 2015 – Member, Clinical and Scientific Review Committee. The Ohio State University. 2015 – Member, Board of Directors – Columbus Academy of Leadership. 2015 – Assigned Judge – 3rd Annual Ohio State University, Department of Internal

Medicine Clinician Scientist Trainee Research Day, 2015 2015 Assigned Judge – Denman Undergraduate Research Forum, The Ohio State

University 2014 – 2015 Assigned Speaker – Recent Developments in treating Indolent Non-Hodgkin

Lymphomas: An NCCN Grand Rounds in the Community Series 2014 – 2015 Assigned Speaker – Latest Developments in Chronic Lymphocytic Leukemia: An

NCCN Grand Rounds in the Community Series 2014 Assigned Judge – Denman Undergraduate Research Forum, The Ohio State

University 2012 – Member – Data Safety Monitoring Board for Medimmune, LLC, 2010 – 2013 Academic Board Member – Georgia Society of Clinical Oncology 2010 – 2013 Member – Speakers Bureau for Spectrum Pharmaceuticals, Inc

Page 3: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

3

2010 – Member – Lymphoma core committee of the Eastern Cooperative Oncology Group

2010 – 2012 Member – National Cancer Institute Chronic Lymphocytic Leukemia Working Group

2010 – 2012 Member – Georgia Health Sciences University Clinical Cancer Research Unit Oversight Committee

2009 – 2012 Member – Developmental Therapeutics, Medical College of Georgia Cancer Research Center

2009 – 2013 Member – Fellowship Selection Committee, Division of Hematology Oncology, Department of Medicine, Georgia Regents University

2009 – 2013 Member – Georgia Regents University Cancer Center 2009 – 2013 Member – Annual Symposium Organizing Committee, Division of Hematology

Oncology, Department of Medicine, Georgia Regents University 2009 – Diplomate, American Board of Medical Oncology 2010 – Diplomate, American Board of Hematology 2007 – Member, American Medical Association 2007 – Member, American Society of Clinical Oncology 2007 – Member, American Society of Hematology 2007 – Member, American Society of Bone Marrow Transplantation 2007 – Member, American Association for Cancer Research 2006 – Diplomate, American Board of Internal Medicine Committee Assignments and Administrative Services Institutional Georgia Regents University Cancer Center Division of Hematology and Division of Hematology and Medical Oncology

Director of Marketing and Outreach, 2012 - 2013 Member, Georgia Regents University Cancer Center Protocol Review and Management Committee, 2012 - 2013

Member, Immunotherapy Discovery Institute, 2010 - 2013 Educational Activities

Time period as mentee

Name Degree Position while mentee

Project Capacity of mentoring

Current position (if known)

2014 -2015

Faraz Fiazuddin

Post Doctoral Fellow

Mentor Internal Medicine Resident at the University of Texas in San Antonio, TX

2009 - 2011

S Thomas Kochuparambil

Internal Medicine Resident

Mentor Hematology/Oncology Fellow at Mayo Clinic, Rochester, MN

Other Educational Programs Didactics for Internal Medicine Residency training program at the Ohio State University Chronic Lymphocytic Leukemia for the Internist, 2015 – current

Page 4: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

4

Didactics for Hematology-Oncology fellowship training program at the Ohio State University Chronic Lymphocytic Leukemia, 2014 – current Core faculty member – Lead Serve Inspire curriculum, Foundational Science II (Med I) of the Ohio State University School of Medicine, 2014 – current Preceptor for Ambulatory Continuity Care Clerkship for First Year medical students at the Ohio State University. 2014 – current. Preceptor for Ambulatory Care Clerkship for Fourth Year medical students (Med 4 portion, Doc 2) at the Ohio State University. 2014 – current. Preceptor for Hematology Specialty Care Elective rotation for Internal Medicine Residency Program at the Ohio State University. 2014 – 2015. Faculty presenter for the NCCN Grand Rounds in the Community Series highlighting the latest developments in Chronic Lymphocytic Leukemia. 2014 – 2015. Didactics for Hematology-Oncology fellowship training program at the Georgia Regents University Non-Hodgkin Lymphomas – 2010 – 2013 Acute and Chronic Leukemias – 2009 – 2013 Hodgkin Lymphoma – 2009 – 2013 Chronic Lymphocytic Leukemia – 2009 – 2013 Post-Transplant Lymphoproliferative Disorders – 2009 – 2013 Statistical Methods – 2009 – 2013 Guest Lecturer on Hematopoietic Stem Cell Transplantation. Master of Physician Assistant Degree Program, Physician Assistant Department, College of Allied Health Sciences, Georgia Regents University. 2011 – 2013 Clinical Trials / Grants / Contract Awards Clinical Trials 1. Open Label Ib/IIa Trial of a Combination of IPH2201 and Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (Innate Pharmaceuticals, Inc.) – Role: National PI. 2015. 2. A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies. (Gilead Inc.) – Role: Institutional PI. 2015. 3. A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas. (Seattle Genetics Inc.) – Role: Institutional PI. 2013. 4. A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia. (Gilead Inc.) – Role: Institutional PI. 2013.

Page 5: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

5

5. An open-label, randomized, phase 3 study of inotuzumab ozogamicin administered in combination with rituximab compared to defined investigator’s choice therapy in subjects with relapsed or refractory CD22-positive aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy. (Pfizer Inc.) – Role: Institutional PI. 2012 – 2013. 6. A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination with Bendamustine/Rituximab (BR) in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma. (Abbott Inc.) – Role: Institutional PI. 2012 – 2013. 7. A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium difficult-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. (Optimer, Inc.) – Role: Institutional PI. 2012 – 2013. 8. An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). (Pfizer Inc.) – Role: Institutional PI. 2012 – 2013. 9. An open label, multicenter phase II study of intravenous SAR3419, an anti-CD19 antibody-maytansine conjugate in patients with relapsed or refractory CD19+Diffuse Large B Cell lymphomas. (Sanofi-Aventis, Inc.) – Role: Institutional PI. 2012 – 2013. 10. International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408/SAR245409 as a monotherapy or as a combination regimen. (Sanofi-Aventis, Inc.) – Role: Institutional PI. 2012 – 2013. 11. A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. (Tragara Pharmaceuticals, Inc) – Role: Institutional PI. 2012 – 2013. 12. A Phase 1b, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia. (Emergent Biosolutions, Inc) – Role: Institutional PI. 2012 – 2013. 13. A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma. (Sanofi-Aventis) – Role: Institutional PI. 2012 – 2013. 14. A Phase 1b, multicenter, open-label, dose-escalation study of SAR245409 to evaluate the safety, tolerability, and clinical activity of SAR245409 in combination with bendamustine and/or rituximab in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia. (Sanofi-Aventis) – Role: Institutional PI. 2012 – 2013. 15. A Phase 1/1b Study of TRU-016 in patients with chronic lymphocytic leukemia or select subtypes of non-Hodgkin’s lymphoma. (Emergent Biosolutions, Inc) – Role: Institutional PI. 2011 – 2013.

Page 6: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

6

16. Once daily intravenous Busulfex as part of reduced-toxicity conditioning for patients with relapsed/refractory Hodgkin’s and non-Hodgkin’s lymphomas undergoing allogeneic hematopoietic progenitor cell transplantation - A multicenter phase II study. (Investigator Initiated) – Role: Co-PI. 2011 – 2013. 17. A phase 1 study of XmAb®5574 to evaluate the safety, tolerability, and pharmacokinetics in patients with relapsed or refractory chronic lymphocytic leukemia. (Xencor, Inc) – Role: Institutional PI. 2011 – 2013. 18. A phase 1b/2 open label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine vs. bendamustine alone in patients with relapsed chronic lymphocytic leukemia. (Emergent Biosolutions, Inc) – Role: Institutional PI. 2010 – 2013. 19. A phase-1 dose-escalation study of the safety and pharmacokinetics of XL147 administered orally daily to subjects with solid tumors or lymphoma – Industry-sponsored (Exelixis, Inc.) – Role: Institutional PI. 2010 – 2012. 20. A multicenter, open-label trial of belinostat in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). (Spectrum Pharmaceuticals Inc.) Role: Institutional PI. 2009 – 2011. 21. A Phase 1/1b Study of TRU-016 in Patients with Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin’s Lymphoma. (Emergent Biosolutions, Inc) – Role: Institutional PI. 2009 – 2011. 22. A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease (Novartis AG, Inc) – Role: Institutional PI. 2009 – 2012. 23. A phase 1, multicenter, open-label, dose-escalation, multidose study of BMS-936561 (MDX-1203) in subjects with advanced/recurrent clear cell renal cell carcinoma or relapsed/refractory b-cell non-Hodgkin’s lymphoma. (Bristol-Myers Squibb) – Role: Institutional PI. 2010. 24. An open-label, multi-center randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease - Industry-sponsored (F. Hoffmann-La Roche Ltd) – Role: Institutional PI. 2009 – 2010. Grants and Contract Awards NCI – R-35 – CA197734-01

The focus and goal of this application is integrating therapeutics that target tumor survival pathways with agents that reverse immune tolerance to facilitate long-term remissions or cure. Title: Targeted Therapy for Leukemia July, 1, 2015 – June 30, 2022 Direct costs: $599,562 Effort: 2.4 calendar (20%) Role: Co-I (PI: Byrd)

Georgia Regents University Cancer Center Translational Research Award

Page 7: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

7

Title: Targeting PI3k/mTOR signaling in treatment of CLL July 2013 Direct costs: $40,000 Role: Co-PI

Lymphoma Research Foundation, Clinical Career Development Award

Title: A PK/PD-based phase I/II clinical trial of a novel IDO inhibitor (1-MT) in patients with CLL May 2013 – May 2016 Direct costs: $225,000 Role: PI

Georgia Regents University Cancer Center Collaborative Research Award

Title: The role of PD-1/PDL-1 axis in chronic lymphocytic leukemia June 2012 Direct costs: $50,000 Role: Co-PI Collaborators: H Shi, PhD and M Mkrtichiyan, PhD

Immunotherapy Discovery Institute Intramural Grant Award, Georgia Regents University

Title: Immune Profiling in Patients with Lymphoid Malignancies Feb 2010 Direct costs: $25,000 Role: PI Mentor: David Munn, M.D.

American Society of Clinical Oncology “Young Investigator Award”

Title: Engineered Small Modular Immune Pharmaceutical targeting of CD37 in Chronic Lymphocytic Leukemia July 2008 – June 2009 Direct costs: $50,000 Mentor: John C Byrd, MD

Research Projects and Publications My NCBI public bibliography can be accessed at the following URL: http://www.ncbi.nlm.nih.gov/sites/myncbi/1Z_-wkzX4e5QJ/bibliograpahy/48964068/public/?sort=date&direction=descending 1. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG,

Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 7. [Epub ahead of print]

2. Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski

SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2015 Oct 7. [Epub ahead of print]

Page 8: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

8

3. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015 Apr 1;1(1):80-7.

4. Shull AY, Noonepalle SK, Awan FT, Liu J, Pei L, Bollag RJ, Salman H, Ding Z, Shi H. RPPA-

based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget. 2015 Jun 10;6(16):14632-45.

5. Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT.

Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma. Clin Cancer Res. 2015 Jul 15;21(14):3160-9

6. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis

M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Onc. April 2015, Vol 1, No. 1.

7. Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W,

Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA. Phase I Dose Escalation Trial of the Novel Proteasome Inhibitor Carfilzomib in Patients with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Leuk Lymphoma. 2015 Mar 11:1-7

8. Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster

PA, Byrd JC. A phase I trial of the Fc engineered CD19 antibody XmAb®5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed chronic lymphocytic leukemia. Blood. 2014 Dec 4;124(24):3553-60

9. Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F,

Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 2015 Jan 8;125(2):284-95

10. Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC,

Gopal AK. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015 Jan;168(1):38-45.

11. Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd

JC. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov;167(4):466-77.

Page 9: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

9

12. Clemmons AB, Hartranft ME, Kota V, Pantin J, Awan FT, Salman H, Jillella AP. Administration of anti-thymocyte globulin: a comparison of two protocols. Bone Marrow Transplant. 2014 Dec;49(12):1535-7

13. Njue A, Colosia A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R,

Kaye JA, Awan F. Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12.e7.

14. Clemmons AB, Evans S, DeRemer DL, Awan FT. Busulfan dosing (Q6 or Q24) with adjusted

or actual body weight, does it matter? J Oncol Pharm Pract. Jul 2014. [Epub]. 15. El-Gamal D, Williams K, LaFollette T, Cannon M, Blachly JS, Zhong Y, Woyach J, Williams

E, Awan F, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC. PKC-beta as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates pre-clinical activity in CLL. Blood. 2014 Aug 28;124(9):1481-91.

16. Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review. Clin Lymphoma Myeloma Leuk. Mar 2014 Oct;14(5):343-355.e6.

17. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE,

Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab (TRU-016), an Anti-CD37 Mono-specific ADAPTIR™ Therapeutic Protein in Chronic Lymphocytic Leukemia. Blood, 2014 Feb 27;123(9):1302-8.

18. Deremer DL, Katsanevas K, Bradley A, Awan FT. Romiplostim resistance in secondary failure of platelet recovery. J Oncol Pharm Pract. 2013 Dec; 19(4):369-72

19. Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013 Oct; 28(5):359-67.

20. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D,

Jillella A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant. 2013 Oct; 48(10):1279-84.

21. Khanal P, Awan F, Nguyen V. Etoposide-induced posterior reversible encephalopathy syndrome. Ann Hematol. 2013 Apr; 92(4):561-2

22. Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, Hamadani M.

Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization. J Oncol. 2012; 2012:931071.

Page 10: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

10

23. Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant. 2012 Jul; 18(7):1128-35

24. Pei L, Choi JH, Liu J, Lee EJ, McCarthy B, Wilson JM, Speir E, Awan F, Tae H, Arthur G, Schnabel JL, Taylor KH, Wang X, Xu D, Ding HF, Munn DH, Caldwell C, Shi H. Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics. 2012 Jun 1; 7(6):567-78.

25. Awan FT, Osman S, Kochuparambil1 ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella

A, Hamadani M. Impact of response to thalidomide-, lenalidomide- or bortezomib containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. Bone Marrow Transplant. 2012 Jan; 47(1):146-8

26. Ustun C, Jillella A, Shah R, Sterling K, Deremer D, Savage N, Awan F, Gossage JR, Dillard

T, Martin PJ. Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD. Bone Marrow Transplant. 2010, Nov; 45(11):1658-60.

27. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Roda J, Cheney C, Mo X,

Lehman A, Jones JA, Flynn JM, Jarjoura D, Desjarlais J, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC. CD19 targeting of chronic lymphocytic leukemia by novel fc-domain engineered monoclonal antibody. Blood. 2010, Feb 11; 115(6):1204-13.

28. Hamadani M, Awan F, Villalona-Calero MA. Malignant thymoma with immunodeficiency

(Good syndrome) associated with mucormycosis. Am J Clin Oncol. 2010 Feb; 33(1):109.

29. Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Jan; 51(1):27-38.

30. Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC,

Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood. 2009 Jan 15; 113(3):535-7.

31. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM.

Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma. 2008 Oct; 49(10):1893-8.

32. Andritsos L, Johnson AJ, Lozanski G, Blum W, Kefauver C,

Awan F, Smith LL, Lapalombella

R, May SE, Wang D, Knight RD, Stark A, Jarjoura D, Chen C, Byrd JC. Higher doses of

lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in chronic lymphocytic leukemia patients. J Clin Oncol. 2008 May 20; 26(15):2519-25.

33. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the

incidence and severity of graft-versus-host disease in patients with acute leukemias undergoing allogeneic stem cell transplantation. Blood. 2008 Apr 1; 111(7):3901-2.

Page 11: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

11

34. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM. Allogeneic

hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant. 2008 Apr; 14(4):480-3.

35. Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr. Dramatic response

to single-agent rituximab in a patient with intravascular lymphoma. Am J Hematol. Am J Hematol. 2007 Dec; 82(12):1120-1

36. Awan F, Hamadani M, Devine S. Paraneoplastic Sweet's syndrome and the pathergy

phenomenon. Ann Hematol. 2007 Aug; 86(8):613-4. 37. Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A. Management of

platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? J Oncol Pharm Pract. 2007 Jun; 13(2):69-75.

38. Awan F, Hamadani M. Gastrointestinal chronic graft-versus-host disease: management

options. J Oncol Pharm Pract. 2007 Mar; 13(1):49-51. 39. Zeng G, Awan F, Otruba W, Muller P, Apte U, Tan X, Gandhi C, Demetris AJ, Monga SP:

Wnt'er in liver: expression of Wnt and frizzled genes in mouse. Hepatology. 2007; 45:195-204.

40. Hamadani M, Awan F: Role of thiamine in managing ifosfamide-induced encephalopathy. J

Oncol Pharm Pract. 2006; 12:237-239. 41. Shafqat S, Khealani BA, Awan F, Abedin SE: Guillain-Barre syndrome in Pakistan: similarity

of demyelinating and axonal variants. Eur J Neurol. 2006; 13:662-665.

42. Jameel MN, Habib Z, Awan F, Ali S, Shafqat S: Acute Encephalitis in Karachi, Pakistan: Clinical spectrum and outcome predictors in a hospitalized population. Pak J Neurological Sci. 2006; 1:1-6.

43. Avan BI, Raza SA, Khokhar S, Awan F, Sohail N, Rashid S, Hamza H: Residents' perceptions

of work environment during their postgraduate medical training in Pakistan. J Postgrad Med 2006; 52:11-18.

44. Shafqat S, Khealani, BA, Awan F, Abedin SE. Comparison analysis of acute axonal

polyneuropathy and classic Guillain-Barre syndrome. J Pak Med Assoc. 2003, 53:4; S-11. 45. Avan BI, Raza SA, Hamza H, Khokhar S, Awan F: Factors influencing the selection of surgical

specialty among Pakistani medical graduates. J Postgrad Med. 2003; 49:197-201. Invited Peer-Reviewed Papers and Reviews 1. Awan FT. How I manage relapsed Chronic Lymphocytic Leukemia. Clinical Oncology News.

September 2015, Vol 10. Can be accessed at URL: http://www.clinicaloncology.com /ViewArticle.aspx?d=Hematologic%2bMalignancies&d_id=149&i=September+2015&i_id=1224&a_id=33511&tab=MostRead

Page 12: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

12

2. Awan, FT, Burke, JM, Horwitz, SM, Zelenetz, AD: B-Cell Malignancies (Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia): ClinicalThought 2015. ePub Aug 12, 2015. Can be accessed at URL: http://www.clinicaloptions.com/Oncology/Treatment %20Updates/B%20Cell%20Malignancies/Module/BCell_Malignancies_Module.aspx

3. Awan, FT: Management of patients with localized Follicular lymphoma. Clinical Care Options, Clinical Thought Oncology. ePub Jul 29, 2015. Can be accessed at URL: http://www.clinicaloptions.com/Oncology/Treatment%20Updates/B%20Cell%20Malignancies/Clinical%20Thoughts/CT%207.aspx

4. Awan, FT: Utility of Kinase Inhibitors in the Management of Relapsed CLL. Clinical Care Options, Clinical Thought Oncology. ePub Apr 27, 2015. Can be accessed at URL: http://www.clinicaloptions.com/Oncology/Treatment%20Updates/B%20Cell%20Malignancies/Clinical%20Thoughts/CT%204.aspx

5. Awan, FT: Ibrutinib and the Management of Patients With del(17p) CLL. Clinical Care Options, Clinical Thought Oncology. ePub Mar 23, 2015. Can be accessed at URL: http://www.clinicaloptions.com/Oncology/Treatment%20Updates/B%20Cell%20Malignancies/Clinical%20Thoughts/CT%203.aspx

6. Awan FT, Byrd JC. New Strategies in Chronic Lymphocytic Leukemia: Shifting Treatment

Paradigms. Clin Cancer Res. 2014 Dec 1;20(23):5869-74. 7. Awan FT. Ibrutinib: targeting the hidden CLL. Blood. 2014 May 22;123(21):3215-6. 8. Awan FT: How I treat previously untreated CLL. J Com Supp Oncol. 2014; 12:119. 9. Awan FT: Obinutuzumab may chart the way to improved QOL for CLL patients. J Com Supp

Oncol. 2014; 12:113-114.

10. Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Aug; 45(8):1259-68.

11. Hamadani M, Awan FT. Remission induction, consolidation and novel agents in development

for adults with acute myeloid leukemia. Hematol Oncol. 2010 Mar; 28(1):3-12.

12. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem-cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2008 May; 14(5):556-67.

Abstracts 1. McWilliams E, Mele JM, Fiazuddin F, Cheney C, Muthusamy N, Awan FT. Targeting the tumor

evasion interaction of NKG2a and its ligand HLA-E increases natural-killer cell activity in chronic lymphocytic leukemia. Abs 1289. Presented at the 57th American Society of Hematology (ASH) Annual Meeting at Orlando, FL, Dec 5-8, 2015.

2. Sharman JP, Shustov AR, Smith MR, Boyd TE, Hagenstad C, Kolibaba KS, Abella S, He J,

Eng C, Hu J, Reddy A, Mitra S, Yasenchak CA, Awan FT. Clinical activity of entospletinib (GS-9973), a selective syk inhibitor, in patients with CLL previously treated with an inhibitor of B-cell receptor pathway signaling. Abs 1744. Presented at the 57th ASH Annual Meeting at Orlando, FL, Dec 5-8, 2015.

Page 13: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

13

3. Woyach JA, Ruppert AS, Awan F, Jones JA, Waymer S, Lozanski G, Muthusamy N, Byrd JC.

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). Abs 2953. Presented at the 57th ASH Annual Meeting at Orlando, FL, Dec 5-8, 2015.

4. El-Gamal D, Hing ZA, Mitchell S, LaFollette TD, Brennan PJ, Flynn JM, Jones JA, Awan F,

Andritsos LA, Blachly JS, Williams K, Harrington BK, Goettl VM, Woyach JA, Lehman AM, Yu L, Byrd JC, Lapalombella R. A novel inhibitor of BET family bromodomains demonstrates in vivo and in vitro potency in B-cell malignancies. Abs 318. Presented at the 57th ASH Annual Meeting at Orlando, FL, Dec 5-8, 2015. Oral Presentation.

5. Rogers KA, Salem G, Stephens DM, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks

KJ, Huang Y, Ruppert AS, Jones JA. A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter’s transformation of chronic lymphocytic leukemia. Abs 2951. Presented at the 57th ASH Annual Meeting at Orlando, FL, Dec 5-8, 2015.

6. Awan F, Gore L, Gao L, Lager J, Costa L. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib

(SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia. Abstract 24, Leuk Lymphoma 1029-2403. Presented at the XVI International Workshop on Chronic Lymphocytic Leukemia at Sydney, Australia, Sep 6-9, 2015. Oral Presentation.

7. McWilliams E, Fiazuddin F, Mele J, Cheney C, Muthusamy N, Byrd J, Awan F. Targeting

natural killer cells in chronic lymphocytic leukemia. Abstract 108, Leuk Lymphoma 1029-2403. Presented at the XVI IWCLL at Sydney, Australia, Sep 6-9, 2015.

8. Robak, T, Wach T, Jones, JA, Owen C, Brown JR, Menter AR, Ysebaert L, Wagner-Johnston

N, Awan F, Taylor K, Schuh A, Cannell P, Morris K, Larratt L, Skotnicki A, Loscertales J, Nathwani A, Badoux X, Hahn U, Jacobsen Pulczynski E, Feugier P, Zini J-M, Dihuydy M-S, Sanhes L, Garcia-Marco J.A., Bosch F, Dreiling L, Peterman S, Cho Y, Dubowy R, Vandenberghe E. Results of a phase 3 randomized controlled study evaluating the efficacy and safety of idelalisib (idela) in combination with ofatumumab (ofa) for previously treated chronic lymphocytic leukemia (CLL).. Abs-598. LB. Presented at the 20th Congress of the European Hematology Association (EHA) at Vienna, Austria, Jun 11-14, 2015.

9. Shull AY, Choi JH, Buckley B, Pei L, Awan FT, Shi H. Transcriptome analysis demonstrates

the ability of the bromodomain inhibitor JQ1 to attenuate expression of common oncogenes heterogeneously expressed among chronic lymphocytic leukemia subsets. Abs 2191. Presented at the American Association of Cancer Research (AACR) Annual Meeting at Philadelphia, PA. Apr 18-22, 2015.

10. Maddocks KJ, Pagel J, Byrd JC, Stromatt S, Awan F. Phase 1b Study of Otlertuzumab (TRU-

016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL). Abs 4671. Presented at the 56th American Society of Hematology (ASH) Annual Meeting at San Francisco, CA. Dec 6-9, 2014.

11. Woyach JA, Awan F, Flinn I, Berdeja J, Wiley EA, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic

Page 14: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

14

Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Abs 1993. Presented at the 56th ASH Annual Meeting at San Francisco, CA. Dec 6-9, 2014.

12. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan F, Hexner E,

Mauro MJ, Sternberg D, Villeneuve M, Emery-Salbert F, Stanek E, Hartmann K, Horny HP, Valent P, Reiter A. Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. Abs 636. Presented at the 56th ASH Annual Meeting at San Francisco, CA. Dec 6-9, 2014. Oral Presentation.

13. Jones JA, Geyer S, Andritsos LA, Awan F, Flynn JM, Maddocks KJ, Bingman, Johnson AJ,

Heerema NA, Brookfield C, Byrd JC, Grever MR. Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study. Abs 329. Presented at the 56th ASH Annual Meeting at San Francisco, CA. Dec 6-9, 2014. Oral Presentation.

14. Wu J, Xu X, Pei L, Lee E, Shull A, Awan F, Wang X, Fan L, Jianyong L, Wei X, Shi H. Genome-

Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients. Abs 3552. Presented at the 56th ASH Annual Meeting at San Francisco, CA. Dec 6-9, 2014.

15. Rogers KA, Woyach JA, Andritsos LA, Awan F, Blum KA, Flynn JM, Jaglowski S, Lozanski

G, Maddocks KJ, Byrd JC, Jones JA. Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib. Abs 1997. Presented at the 56th ASH Annual Meeting at San Francisco, CA. Dec 6-9, 2014.

16. Maddocks K, Flynn JM, Andritsos LA, Awan F, Woyach JA, Grever MR, Stefanos M, Lynch

J, Johnson AJ, Byrd JC, Jones JA. A phase 2 study of the BTK inhibitor ibrutinib in genetic risk-stratified relapsed and refractory patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). ABSSUB-5912. Presented at the 19th Congress of the EHA at Milan, Italy, Jun 12-15, 2014.

17. Maddocks KJ, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L,

Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Disease progression on ibrutinib therapy is uncommon and is associated with the acquisition of resistance mutations: A single center experience of 267 patients. ABSSUB-5899. Presented at the 19th Congress of the EHA, Jun 12-15, 2014.

18. Woyach JA, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon

A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Maddocks KJ. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. J Clin Oncol 32:5s, 2014 (suppl; abstr 7010). Presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting at Chicago, IL. May 30 – June 3, 2014.

19. Trneny M, Verhoef G, Dyer MJS, Yehuda DB, Patti C, Canales M, López A, Awan F, Montgomery P, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford JA, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM. Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887). J Clin Oncol 32:5s, 2014 (suppl;

Page 15: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

15

abstr 8506). Presented at the 50th ASCO Annual Meeting at Chicago, IL. May 30 – June 3, 2014.

20. Noonepalle SK, Shull A, Awan FT, Pei L, Ding Z, Shi H. Profiling signaling pathways in chronic

lymphocytic leukemia using reverse phase protein array. Abs 5180. Presented at the AACR Annual Meeting at San Diego, CA. Apr 5-9, 2014.

21. Shull A, Luo J, Choi J, Pei L, Awan FT, Lee E, Liu J, Buckhaults P, Yan X, Chiorazzi N, Shi

H. Identifying differential gene expression and splicing events in chronic lymphocytic leukemia patients through whole transcriptome profiling. Abs 5182. Presented at the AACR Annual Meeting at San Diego, CA. Apr 5-9, 2014.

22. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan F, Hexner E,

Mauro M, Morariu R, Squier M, Villeneuve M, Emery-Salbert F, Coombs J, Hartmann K, Horny HP, Valent P, Reiter A. Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the global D2201 trial. Abs 106. Presented at the 55th ASH Annual Meeting at New Orleans, LA. Dec 7-10, 2013. Oral Presentation.

23. Robak T, Hellman A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel JM, Mato M, Byrd JC, Awan FT, Hebart H, Garcia-Marco JA, Hill BT, Hallek M, Stromatt S, Jaeger U. Phase 2 study of otlertuzumab (Tru-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2013 122:2860. Presented at the 55th ASH Annual Meeting at New Orleans, LA. Dec 7-10, 2013.

24. Brown JR, Davids MS, Rodon J, Abrisqueta P, Egile C, Ruiz-Soto R, Awan FT. Update on

the safety and efficacy of the pan class I PI3k inhibitor SAR245408 (XL147) in chronic lymphocytic leukemia and non-hodgkin’s lymphoma patients. Blood 2013 122:4170. Presented at the 55th ASH Annual Meeting at New Orleans, LA. Dec 7-10, 2013.

25. Zakharia Y, Kota V, Mansour J, Prabhakar R, Lan L, Awan FT, Jillella A. Serum alkaline

phosphatase level on day 4 of g-csf administration could be a simple yet practical surrogate marker for CD34 mobilization and collection. Blood 2013 122:4519. Presented at the 55th ASH Annual Meeting at New Orleans, LA Dec 7-10, 2013.

26. Maddocks K, Pagel JM, O'Brien S, Byrd JC, Stromatt S, Awan FT. Phase 1b study of

otlertuzumab (Tru-016), an anti-CD37 ADAPTIRTM protein, in combination with rituximab in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood 2013 122:4165. Presented at the 55th ASH Annual Meeting in New Orleans, LA Dec 7-10, 2013.

27. Chand AR, Simmons J, Awan FT, Jillella AP, Kolhe RB, Kota V. Congestive Heart Failure

(CHF) during induction in acute promyelocytic leukemia (APL) patients. Blood 2013 122:3898. Presented at the 55th ASH Annual Meeting in New Orleans, LA Dec 7-10, 2013.

28. Awan F, Shi H, Addis D, Gregory J, Munn D. Targets for reversing T-cell anergy in CLL. Abs.

1.3 Presented at the 15th IWCLL Meeting at Cologne, Germany. Sept 9-11, 2013.

Page 16: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

16

29. Jillella A, Kolhe RB, Awan F, Natrajan K, Kota V. A successful model to decrease early and preventable deaths in Acute Promyelocytic Leukemia (APL) through the use of a simplified algorithm and expert support in experienced as well as smaller leukemia treatment centers in the US. Abs. C17. Presented at the 6th International Symposium on APL at Rome, Italy. Sept 29 – Oct 2, 2013.

30. Kolhe R, Rojiani A, Jillela A, Awan F, Arati C, Simmons J, Kota V. Utility and impact of early t(15:17) identification by fluorescence in situ hybridization (FISH) in clinical decision making for patients in acute promyelocytic leukemia (APL). Abs. P16. Presented at the 6th International Symposium on APL at Rome, Italy. Sept 29 – Oct 2, 2013.

31. Chand AR, Simmons J, Awan F, Anand J, Kolhe RB, Kota V. Congestive heart failure (CHF) during induction in acute promyelocytic leukemia (APL) patients. Abs. P17. Presented at the 6th International Symposium on APL at Rome, Italy. Sept 29 – Oct 2, 2013.

32. Chand AR, Awan F, Simmons J, Anand J, Kolhe R, Kota V. Do steroids given prophylactically along with chemotherapy during induction for acute promyelocytic leukemia (APL) mask differentiation syndrome? Abs. P18. Presented at the 6th International Symposium on APL at Rome, Italy. Sept 29 – Oct 2, 2013.

33. Jillella A, Awan FT, Pantin JM, Kolhe RB, Kota V. Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts. J Clin Oncol 31, 2013 (suppl; abstr 7091). Presented at the 49th ASCO Annual Meeting at Chicago, IL. May 31 – June 4, 2013.

34. Chaudhary L, Awan FT, Cumpston A, Tse WT, Craig M, Hamadani M. Efficacy and cost of peripheral blood stem cell (PBSC) mobilization with low-dose cyclophosphamide (LD-CY) compared with plerixafor (P) in multiple myeloma (MM) patients (pts) treated with novel induction therapies. J Clin Oncol 31, 2013 (suppl; abstr 7040). Presented at the 49th ASCO Annual Meeting at Chicago, IL. May 31 – June 4, 2013.

35. Raval P, Kota V, Zakharia Y, Carter G, Christopherson K, Awan FT, Pantin JM, Jillella AP. Congestive heart failure (CHF) in acute myeloid leukemia patients during induction. J Clin Oncol 31, 2013 (suppl; abstr 7105). Presented at the 49th ASCO Annual Meeting at Chicago, IL. May 31 – June 4, 2013.

36. Awan FT, Kochuparambil S, Craig M, Cumpston A, Leadmon S, DeRemer D, Watkins K, Pantin J, Kota V, Jillella A, Hamadani M. A multicenter analysis of intermediate-dose cyclophosphamide versus plerixafor and granulocyte colony stimulating factor for PB progenitor cell mobilization in patients with multiple myeloma treated with novel induction chemotherapies. Biol Blood Marrow Transplant, Feb 2013; 19:2, S182-183. Presented at the ASBMT Annual Meeting at Salt Lake City, UT. Feb 13-17, 2013.

37. Bradley A, Evans S, DeRemer D, Awan FT. Intravenous busulfan pharmacokinetics in conditioning regimens for allogeneic hematopoietic stem cell transplantation: Impact of dosing weight. Biol Blood Marrow Transplant, Feb 2013; 19:2, S373-374. Presented at the ASBMT Annual Meeting at Salt Lake City, UT. Feb 13-17, 2013.

38. Awan F, Jaeger U, Rifkin R, Thirman MJ, Byrd JC, Hallek M, Stromatt S, Pagel JM. Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM Protein, in Combination with Bendamustine vs.

Page 17: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

17

Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia. Abs 1795. Presented at the 54th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2012.

39. Woyach JA, Awan F, Flinn IW, Enoch R, Foster PA, Byrd JC. Final Results of a Phase I Study

of the Fc Engineered CD19 Antibody XmAb®5574 (MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Abs 2894. Presented at the 54th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2012.

40. Lee EJ, Liu J, Speir E, Wilson J, Joshi H, Pei L, Luo J, Awan F, Munn D, Yan XJ, Chiorazzi N, Shi H. DNA Hypomethylation Leads to Aberrant Expression of PD-1 in Chronic Lymphocytic Leukemia. Abs 3504. Presented at the 54th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2012.

41. Luo J, Choi J, Pei L, Awan F, Lee EJ, Liu J, Shull A, McCarthy BA, Wilson JM, Taylor KH, Wang X, Buckhaults PJ, Munn DH, Caldwell CW, Yan XJ, Chiorazzi N, Shi H. Genome-Wide DNA Methylation Landscape Defines IGHV Mutated and Unmutated B Cell Chronic Lymphocytic Leukemias. Abs 526. Presented at the 54th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2012.

42. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan F, Hexner E,

Mauro MJ, Morariu R, Squier M, Villeneuve M, Emery-Salbert F, Hartmann K, Horny HP, Valent P, Reiter A. KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. Abs 799. Presented at the 54th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2012. Oral Presentation.

43. Jillella AP, Sadek I, Morrison D, Natrajan K, Awan FT, Kolhe R, Kota V. A simple but effective

model to decrease early deaths in acute promyelocytic leukemia (APL). J Clin Oncol 30, 2012 (suppl; abstr 6573). Presented at the 48th ASCO Annual Meeting at Chicago, IL. June 1-5, 2012.

44. Kolhe R, Jillella AP, Natrajan K, Awan FT, Manaloor E, Kota V. miRNA expression profiling

of CD20+ plasma cell myeloma (PCM): Upregulation of miR-155 shedding new insight into disease biology and clinicopathologic behavior. J Clin Oncol 30, 2012 (suppl; abstr 8108). Presented at the 48th ASCO Annual Meeting at Chicago, IL. June 1-5, 2012.

45. Morrison D, Kochuparambil ST, DeRemer D, Kota V, Jillella A, Awan F. Clinical Practice Guideline for the treatment of BK-Virus induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. Volume 18 Issue 2. Presented at the American Society of Bone Marrow Transplant (ASBMT) Annual Meeting at San Diego, CA. Feb 1-5, 2012.

46. Awan FT, Pagel JM, Andritsos LA, Gopal AK, Furman R, Spurgeon S, Limayo DD, Stromatt

S, Byrd JC. Phase 1 Study of Tru-016, An Anti-CD37 SMIPTM Protein in Naïve and Relapsed and/or Refractory CLL Patients. Abs.1792 Presented at the 53rd ASH Annual Meeting at San Diego, CA. Dec 10-13, 2011. “Selected for Highlights of ASH”.

47. Hamadani M, Kochuparambil S, Osman S, Speir E, Craig M, Deremer D, Cumpston A,

Morrison DD, Leadmon S, Sterling K, Bunner P, Sterrett M, Kota V, Jillella A, Awan FT. Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma

Page 18: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

18

Treated with Novel Induction Chemotherapies – A Multicenter Analysis. Abs. 313 Presented at the 53rd ASH Annual Meeting at San Diego, CA. Dec 10-13, 2011. Oral Presentation.

48. Brown JR, Davids MS, Rodon J, Abrisqueta P, DeCillis AP, Rockich K, Egile C, Kelly A, Xu

Y, Lager J, Awan FT. Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. Presented at the 53rd ASH Annual Meeting at San Diego, CA. Dec 10-13, 2011.

49. Pagel JM, Spurgeon S, Awan FT, Blum KA, Lanasa M, Flinn IW, Stromatt S, Byrd JC, Gopal

AK. Phase 1 Study of TRU-016, An Anti-CD37 SMIPTM Protein in Relapsed and/or Refractory NHL Patients. Abs. 1636 Presented at the 53rd ASH Annual Meeting at San Diego, CA. Dec 10-13, 2011.

50. Kochuparambil ST, Deremer D, Mabel E, Jillella A, Awan FT. Optimizing the efficacy of

Plerixafor as a salvage option in poor mobilizers following chemotherapy plus G-CSF. Volume 17 Issue 2. Presented at the ASBMT Annual Meeting at Honolulu, HI. Feb 17-21, 2011

51. Parikh J, Kota V, Awan F, Jillella A. Improving autologous transplant outcomes in the elderly

(>70years) population. Presented at the ASBMT Annual Meeting at Honolulu, HI. Feb 17-21, 2011

52. Awan F, Osman S, Kochuparambil S, Remick S, Abraham J, Craig M, Jillella A, Hamadani

M. Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis. Blood, Nov 2010; 116: 1351. Presented at the 52nd ASH Annual Meeting at Orlando, FL. Dec 4-7, 2010.

53. Kochuparambil ST, Natrajan K, Jillella AP, Hamadani SM, Awan F. Allogeneic

Transplantation Following Reduced Intensity Conditioning with Fludarabine and Melphalan In Patients with Advanced Myelofibrosis Is Associated with Unacceptable Rates of Acute Graft-Vs-Host Disease and Non-Relapse Mortality. Blood, Nov 2010; 116:4552. Presented at the 52nd ASH Annual Meeting at Orlando, FL. Dec 4-7, 2010.

54. Awan F, Deremer D, Mebel E, Kochuparambil ST, Jillella A. Utility of Plerixafor In Addition to

Chemotherapy and G-CSF Mobilization Regimens. Blood, Nov 2010, 116:4443. Presented at the 52nd ASH Annual Meeting at Orlando, FL. Dec 4-7, 2010.

55. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Cheney C, Mo X, Lehman

A, Jones JA, Flynn JM, Jarjoura D, Baiocchi RA, Desjarlais J, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC. CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody. Blood, Nov 2009; 114: 3725. Presented at the 51st ASH Annual Meeting at New Orleans, LA. Dec 5-8, 2009.

56. Davanzo L, Awan F, Hamadani M, Benson DM, Devine DM. Stem cell transplantation for

peripheral T-cell Lymphomas: Single-Institution Experience and Outcomes. Presented at the 11th Annual Scientific Meeting of the Ohio State University Comprehensive Cancer Center at Columbus, OH. Feb 20, 2009

57. Awan F, Kay N, Davis M, Wu W, Leung N, Jelinek DF, Tschumper R, Secreto C, Lin TS,

Grever MR, Shanafelt T, Zent CS, Call TS, Heerema NA, Lozanski G, Byrd JC, Lucas D. Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic

Page 19: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

19

Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab. Blood, Nov 2008; 112: 2105. Presented at the 50th ASH Annual Meeting at San Francisco, CA. Dec 6-9, 2008.

58. Awan FT, Hamadani M, Lin TS, Porcu P, Blum KA, Benson Jr DM., Devine SM. Comparison

of allogeneic vs. autologous transplantation for follicular lymphoma after transformation into diffuse large B-cell lymphoma. J Clin Oncol 26: 2008 (May 20 suppl; abstr 7046). Presented at the 44th ASCO Annual Meeting at Chicago, IL. May 30-Jun 3, 2008.

59. Hamadani M, Awan FT, Elder P, Devine SM. Statins reduce acute graft-versus-host disease

in patients with acute leukemia undergoing allogeneic transplantation. J Clin Oncol 26: 2008 (May 20 suppl; abstr 7040). Presented at the 44th ASCO Annual Meeting at Chicago, IL. May 30-Jun 3, 2008.

60. Hamadani M, Awan FT, Elder P, Lin TS, Andritsos L, Blum W, Blum KA, Devine SM. Rapid

Engraftment and Low Rates of Graft-Versus-Host Disease (GVHD) Following Reduced Intensity Conditioning (RIC) with Fludarabine/Busulfan/ATG (FBA) and Stem Cell Transplantation (SCT) Using Unrelated Donors (URD). Biol Blood Marrow Transplant Vol 14, Issue 2s Feb, 2008. Presented at the ASBMT Annual Meeting at San Diego, CA. Feb 13-17, 2008

61. Hamadani M, Awan F, Elder P, Porcu P, Lin T, Blum K, Scholl D, Devine SM. Allogeneic

Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: Evidence of Graft-Versus-Lymphoma Effect. Blood, Nov 2007; 110, Issue 11. Presented at the 49th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2007.

62. Andritsos LA, Johnson AJ, Blum W, Kefauver C, Awan F, Smith L, Lapalombella R, Wang D,

Knight RD, Chen C, Byrd JC Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses. Blood, Nov 2007; 110, Issue 11. Presented at the 49th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2007.

63. Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K,

Devine SM.High Rates of Early Donor Chimerism and Low Risk of Chronic GVHD Can Be Achieved in Poor Risk Patients Undergoing Unrelated Donor Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Incorporating Fludarabine, Busulfan, and Rabbit ATG. Blood, Nov 2007; 110, Issue 11. Presented at the 49th ASH Annual Meeting at Atlanta, GA. Dec 8-11, 2007.

64. Awan F, Ganesh S. Intra-Pulmonary Shunt: An Uncommon Source of Paradoxical Emboli.

Presented at the 29th annual meeting of the Society of General Internal Medicine, at Los Angeles, CA, Apr 28, 2006.

65. Awan F, Otruba W, Muller P, Zeng G, Monga SP. Wnt’er in Mouse Liver. Faseb Journal 20

(5): A1089-A1090 Part 2, Mar 7 2006. Presented at the American Society of Investigative Pathology meeting at San Francisco, CA. Apr 4, 2006.

66. Apte U, Muller P, Awan F, Otruba W, Cieply B, Monga SP. Wnt/β-Catenin pathway activation

during normal postnatal liver growth and development. Faseb Journal 20 (5): A1089-A1089 Part 2, Mar 7 2006. Presented at the American Society of Investigative Pathology meeting at San Francisco, CA. Apr 4, 2006.

Page 20: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

20

67. Shafqat S, Awan F, Habib Z. Trends in Stroke Recovery: Initial Results form the AKUH study. Presented at the American Physical Therapy Association Meeting at Nashville, TN, Feb 2004.

68. Shafqat S, Awan F, Akhtar N, Abbasi M, Ahmed N, Habib Z. Intracerebral hemorrhage in

patients with cardiac left ventricular hypertrophy. Stroke 34 (1): 277; Jan 2003. 69. Shafqat S, Awan F, Habib Z. Trends in Stroke Recovery: Initial Results form the AKUH study”.

Journal of Neurologic Physical Therapy. 27 (4): 164; 2003. 70. Shafqat S, Awan F, Akhtar N, Abbasi M, Ahmed N, Habib Z. Chronic severity of hypertension

does not predict severity of hypertensive brain hemorrhage. Presented at the 28th International Stroke Conference of the American Heart Association at Phoenix, AR. Feb 13-15, 2003.

71. Awan F, Memon SB, Abbasi M, Afzal A, Alam A, Ali SA, Anwer SA, Choudhary KS, Rafique

G. β-Thalassemia Major. Parental knowledge and awareness in Pakistan. Presented at the 11th European Students Conference, at Berlin, Germany. Nov 16-22, 2000.

72. Awan F, Kakepoto GN, Khurshid M. Clinical presentations of Multiple Myeloma. Presented at

the 6th annual meeting of the Pakistan Association of Pathologists, 1999.

Invited Presentations

1. Farrukh Awan, MD. Co-Faculty Trainer for Idelalisib Speakers Bureau Meeting. San Francisco, CA. Oct 17, 2015.

2. Farrukh Awan, MD. Updates in the Management of CLL. Presented as the West Virginia

Oncology Society Annual Fall Meeting. Morgantown, WV. Oct 15, 2015. 3. Farrukh Awan, MD. Management of CLL. Presented as part of the “Northern Ohio Blood

Cancer Conference” organized by the Leukemia Lymphoma Society – a free educational program for patients, caregivers and family members. Cleveland, OH. Oct 03, 2015.

4. Farrukh Awan, MD. Early Management of CLL. Presented as part of the “Living with CLL”

series organized by the Leukemia Lymphoma Society – a free educational program for patients, caregivers and family members. Columbus, OH. Jun 06, 2015.

5. Farrukh Awan, MD. CLL Management. Thought Leader Presentation. Presented at the Genentech, Inc. National Sales Meeting, Las Vegas, NV. Jan 27, 2015.

6. Farrukh Awan, MD. CLL Updates. Presented at the Leukemia Lymphoma Society Midwest

Chapter ASH review, Pittsburgh, PA. Jan 16, 2015.

7. Farrukh Awan, MD. Recent Developments in Treating Indolent Non-Hodgkin’s Lymphoma: An NCCN Grand Rounds in the Community Series. Presented at William Beaumont Hospital, Royal Oak, MI. December 16, 2014.

8. Farrukh Awan, MD. Emerging Treatment Paradigms for the Management of CLL. James M. Perelman Visiting Professorship in Oncology. Presented at the Akron General Hospital and McDowell Cancer Institute Hematology and Oncology Summit. Akron, OH. Nov 05, 2014.

Page 21: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

21

9. Farrukh Awan, MD. Current Updates in the Treatment of Chronic Lymphocytic Leukemia: Presented at the Charles L. Spurr Piedmont Oncology Symposium of the Wake Forest University School of Medicine. Myrtle Beach, SC. Oct 24, 2014.

10. Farrukh Awan, MD. Recent Developments in Treating Indolent Non-Hodgkin’s Lymphoma:

An NCCN Grand Rounds in the Community Series. Presented at St. Joseph Hospital. Orange, CA. September 30, 2014.

11. Farrukh Awan, MD. Latest Developments in Chronic Lymphocytic Leukemia: An NCCN

Grand Rounds in the Community Series. Presented at the Medicine Grand Rounds of Baptist Health Hospital, Madisonville, KY. Aug 21, 2014.

12. Farrukh Awan, MD. Latest Developments in Chronic Lymphocytic Leukemia: An NCCN

Grand Rounds in the Community Series. Presented at the Medicine Grand Rounds of Clarion Hospital, Clarion, PA. Aug 6, 2014.

13. Farrukh Awan, MD. Latest Developments in Chronic Lymphocytic Leukemia: An NCCN

Grand Rounds in the Community Series. Presented at the Oncology Grand Rounds of Washington Cancer Institute, Washington, DC. Aug 1, 2014.

14. Farrukh Awan, MD. Latest Developments in Chronic Lymphocytic Leukemia: An NCCN

Grand Rounds in the Community Series. Presented at the Oncology Grand Rounds of Edwards Comprehensive Cancer Center of the Marshall University School of Medicine, Huntington, WV. Jul 11, 2014.

15. Farrukh Awan, MD. Updates in the management of Chronic Lymphocytic Leukemia.

Presented at the Oncology Grand Rounds of Edwards Comprehensive Cancer Center of the Marshall University School of Medicine, Huntington, WV. Jul 11, 2014.

16. Farrukh Awan, MD. Management of CLL. Presented as the West Virginia Oncology Society

Annual Spring Meeting. Morgantown, WV. May 9, 2014. 17. Farrukh Awan, MD. Chronic Lymphocytic Leukemia, Past, Present and Future. Presented

at the Hematology/Oncology Grand Rounds at The Aga Khan University, Karachi, Pakistan. Jan 9, 2013.

18. Farrukh Awan, MD. Hematopoietic Stem Cell Transplantation. Presented at the 47th Annual

Primary Care and Family Medicine Symposium in Augusta, GA. April 15, 2012.

19. Farrukh Awan, MD. Personalized medicine and its impact on cancer care. Presented at the 10th Annual Georgia Life Sciences Summit in Atlanta, GA. Sept 27, 2011.

20. Farrukh Awan, MD. Updates in the management of Non-Hodgkin Lymphomas. Presented at the Fifth Annual GHSU Cancer Center and Section of Hematology/Oncology Symposium in Savannah, GA. Sept 23-24, 2011.

21. Farrukh Awan, MD. Updates in the management of indolent Non-Hodgkin Lymphomas. Presented at the Fourth Annual MCG Cancer Center and Section of Hematology/Oncology Symposium in Savannah, GA. Oct 1-2, 2010.

Page 22: Farrukh Tauseef Awan, MD

Farrukh Tauseef Awan, MD Updated: 5/5/2016

22

22. Farrukh Awan, MD. Chronic Lymphocytic Leukemia Medicine Grand Rounds presentation at the Medical College of Georgia, Augusta, GA. Nov 4, 2009.

23. Farrukh Awan, MD. Emerging paradigms in the management of Chronic Lymphocytic

Leukemia. Presented at the Third Annual MCG Cancer Center and Section of Hematology/Oncology Symposium in Savannah, GA. Sep 11-13, 2009.

24. Farrukh Awan, MD. Antibodies for the Treatment of Cancer: A Prototype for the

Development of Targeted Therapies. Presented at the Annual Meeting of the American Society for Clinical Laboratory Science in Columbus, OH. May 6-8, 2009.